# Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)

> **NCT04547946** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 3 (actual)

## Conditions studied

- Malignant Melanoma

## Interventions

- **DRUG:** dabrafenib + trametinib

## Key facts

- **NCT ID:** NCT04547946
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-15
- **Primary completion:** 2022-06-07
- **Final completion:** 2022-06-07
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2023-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04547946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04547946, "Observational Study for Melanoma Adjuvant Treatment With Tafinlar® + Mekinist® (Dabrafenib + Trametinib)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04547946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*